OAKLAND, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Promaxo today announced the initial close of its Series C financing, with participation from New Science Ventures and Amara Ventures, as well as the successful closing of a $100M credit facility. The new capital will support expanded manufacturing capacity, backlog reduction, and new regulatory filings..

加利福尼亚州奥克兰，2026年10月22日（环球电讯社）——Promaxo今日宣布完成其C轮融资的首次关闭，New Science Ventures和Amara Ventures参与投资，并成功达成一项1亿美元的信贷额度。新资金将用于扩大制造产能、减少订单积压以及提交新的监管申请。

The growth capital provides Promaxo with both dilutive and non-dilutive funding as new dedicated prostate-biopsy reimbursement codes from the Centers for Medicare & Medicaid Services (CMS) highlight the patient-care benefits of Promaxo’s minimally-invasive biopsy and treatment pathways. The initial close included participation from UAE-based Amara Ventures and New Science Ventures, a VC firm based in Connecticut and London..

随着美国医疗保险和医疗补助服务中心（CMS）新设立的专用前列腺活检报销代码凸显了Promaxo微创活检和治疗路径在患者护理方面的优势，这笔增长资本为Promaxo提供了股权稀释型和非股权稀释型资金。首轮关闭吸引了阿联酋的Amara Ventures以及总部位于康涅狄格州和伦敦的风险投资公司New Science Ventures参与。

Promaxo’s platform advances patient care by combining point-of-care image-guided interventions with AI and robotics. Its portable MRI system is the first in the United States to receive FDA 510(k) clearance for prostate biopsy and treatment across a broad range of healthcare settings. Promaxo is pursuing FDA clearance for its robotic platform and AI-based cancer risk-scoring tool to further improve the precision and predictability of prostate interventions..

Promaxo的平台通过将床旁影像引导介入与人工智能和机器人技术相结合，推动患者护理的进步。其便携式MRI系统是美国首个获得FDA 510(k)许可、适用于广泛医疗场景的前列腺活检和治疗系统。Promaxo正在为其机器人平台和基于人工智能的癌症风险评分工具寻求FDA许可，以进一步提高前列腺介入治疗的精确性和可预测性。

“We are excited to invest in Promaxo’s Series C round and support the next phase of growth and commercialization of its point-of-care MRI platform, powered by AI and robotics, for precision care. Promaxo’s differentiated approach to image-guided interventions—combining innovative MRI technology, data driven robotics, and advanced AI tools—has the potential to transform how precision oncological procedures are delivered and reshape the procedural care paradigm,” said Somu Subramaniam, Founder and Managing Partner of New Science Ventures..

“我们很高兴能投资 Promaxo 的 C 轮融资，并支持其由人工智能和机器人技术驱动、面向精准医疗的床旁 MRI 平台进入下一阶段的成长与商业化。Promaxo 在影像引导介入领域独具特色的方法——融合创新 MRI 技术、数据驱动的机器人技术和先进的人工智能工具——有望变革精准肿瘤手术的实施方式，重塑手术诊疗范式。”New Science Ventures 创始人兼管理合伙人 Somu Subramaniam 表示。

'This financing is a vote of confidence in our execution and in the markets, we serve,' said Dr. Amit Vohra, Founder and CEO of Promaxo. 'Combining credit with equity lets us invest in value creation priorities while limiting dilution for our shareholders.'

“这笔融资是对我们的执行能力以及我们所服务市场的信心投票，”Promaxo创始人兼首席执行官Amit Vohra博士表示。“将债权融资与股权融资相结合，使我们能够投资于价值创造的重点领域，同时限制对股东的稀释。”

According to the National Cancer Institute (NCI), around 3.3 million men currently live with prostate cancer in the US, with an estimated 333,830 new cases and 36,320 deaths projected for 2026. Over two million prostate biopsies are performed annually, and the total US prostate screening, biopsy and treatment market is valued at about $10 billion.

根据美国国家癌症研究所（NCI）的数据，目前美国约有330万男性患有前列腺癌，预计2026年新增病例将达到333,830例，死亡人数为36,320人。每年进行的前列腺活检超过200万例，美国前列腺筛查、活检和治疗市场的总价值约为100亿美元。

Additionally, Promaxo is seeking to expand into other adjacent indications, such as female pelvic, kidney, breast, and colorectal cancers..

此外，Promaxo 正寻求拓展至其他相邻适应症，如女性盆腔癌、肾癌、乳腺癌和结直肠癌。

About Promaxo

关于 Promaxo

Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform. Based in Oakland, California, and backed by over 250 patents, the Company’s mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities.

Promaxo 由一群企业家和医疗健康创新者创立，旨在开发一种微创、以患者为中心的 MRI 与机器人平台。公司总部位于加利福尼亚州奥克兰，拥有超过 250 项专利支持，其使命是通过先进的医学影像、机器人技术和人工智能能力改善人们的生活。

With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient diagnosis and interventions. To learn more about the platform technologies, please visit:.

凭借紧凑型且适应性强的MRI系统，Promaxo通过提升患者诊断和干预的质量与速度，重新定义护理标准。欲了解更多关于平台技术的信息，请访问：

Website :

网站：

https://www.promaxo.com

https://www.promaxo.com

LinkedIn :

领英：

https://www.linkedin.com/company/promaxo

https://www.linkedin.com/company/promaxo

Twitter :

推特：

@Promaxo

@Promaxo

Contact:

联系方式：

hello@promaxo.com

hello@promaxo.com